349.05
+0.24%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IND Swift Laboratories
Its shares trade on NSE under the ticker INDSWFTLAB.NS. It has been listed since 15 March 2002. In the fiscal year to 31 March 2026, it reported revenue of ₹6.41bn and net income of ₹414.2m. At that date it held total assets of ₹16.73bn and shareholders' equity of ₹13.84bn.
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. The company is API partner for many organizations both in generic and innovative domains. The firm offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The firm offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Mar 2002
- Employees
- 1,496
- Website
- indswiftlabs.com ↗
Leadership
Pay as last reported
- Shri. Navrattan MunjalExecutive Chairman of the Board, Managing Director, since 1995₹36.2m
- Mr. Gagan AggarwalChief Financial Officer
- Shri. Vikas NarendraPresident - US Operations
- Rakesh BahugunaSenior Vice President - QC
- Anurag ChaturvediSenior Vice President - Marketing
- Varun ChhabraSenior Vice President - Marketing
- Ashok PrasadSenior Vice President - R&D
- Sandeep SinghSenior Vice President - Procurement
- Saranjai TyagiSenior Vice President - QA
- Shri. Pardeep VermaCompliance Officer, Company Secretary, AVP - Corporate Affairs, since 2022
- Shri. Himanshu JainJoint Managing Director, Whole Time Director₹28.9m
- Shri. Rishav MehtaWhole Time Director, since 2010₹14.5m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ind-Swift manufactures Advanced Intermediates for pharmaceuticals with 25 APIs covered.
- Ind-Swift offers reference standards and impurities for over 25 APIs under BP and EP standards.
- Ind-Swift's research center spans 40,000 square feet for API process technology development.
Weaknesses
- Ind-Swift's headquarters is in Chandigarh, India, limiting global reach.
- Ind-Swift's IPO listing date is 15 March 2002, which is outdated.
- Ind-Swift employs 1,496 employees, which is small for a global pharmaceutical firm.
Opportunities
- Ind-Swift can expand API partnerships in the generic pharmaceutical sector.
- Ind-Swift can leverage its 40,000 square feet research center for new therapeutic categories.
- Ind-Swift can increase its impurity portfolio for more API supply chains.
Threats
- Ind-Swift faces competition from other API manufacturers in the Indian pharmaceutical sector.
- Ind-Swift's reliance on BP and EP standards may limit its market in non-EU regions.
- Ind-Swift's small employee count of 1,496 may hinder rapid scaling in global markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.